The pharmaceutical industry has a crucial role in modern healthcare, but it also has a significant environmental footprint. From large-scale solvent use and carbon emissions to water pollution and ...

Truist analyst Michael Swartz lowered the firm’s price target on LCI Industries (LCII) to $80 from $108 and keeps a Hold rating on the shares ...

Baird downgraded LCI Industries (LCII) to Neutral from Outperform with a price target of $100, down from $130. The firm reset its rating baseline, with Neutral as the default setting for its ...

Iris Bincovich Innocan Pharma's CEO stated: "It is an honour to receive the continued support of our investors, who have placed their trust in Innocan's proprietary technology". The Company ...

The Trump administration’s threat of pharmaceutical tariffs could risk significant political backlash, as the drug industry and outside experts are raising red flags over worsening shortages and ...

Global drugmakers’ stocks dropped across the board today after U.S. President Donald Trump reiterated plans for a “major” tariff on pharmaceutical imports, threatening an interwoven supply ...

Amid a broader selloff in the biopharma sector on Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) dropped ~6% after announcing a $145M settlement to resolve certain antitrust claims filed regarding ...

Following the recently granted patent in India for a prolonged-release pharmaceutical formulation using liposomes to encapsulate CBD, Innocan is actively advancing its efforts to strengthen ...

In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets ...

What to do? Within our space, the companies facing this decision are typically large pharmaceutical organizations—household names like Pfizer, GSK and Novartis. For these companies, there are a ...

For the five years between 2025 and 2029, as much as 103.2 billion euros ($113 billion) of planned capital and R&D expenditures in EU’s biopharma sector could leave the region, according to ...

By shifting profits offshore in 2019, Pfizer allegedly “carried out what could be the largest tax-dodging scheme in the history of Big Pharma,” Sen. Ron Wyden, D-Oregon, ranking member of the ...